Elucidata Corporation, a Cambridge, MA- and New Delhi, India-based data science company focused on developing tools and software solutions for drug discovery, raised $1.7m in seed funding.
The round was led by Hyperplane Venture Capital with participation from some angels.
The company intends to use the funds to expand its team, add to its operations in New Delhi, and launch new discovery tools.
Co-founded in 2015 Abhishek Jha and Swetabh Pathak, Elucidata provides a data-driven drug discovery platform for scientists to analyze complex datasets and enable drug discovery. PollyTM, the company’s cloud-based data analytics platform, aims to transform the end-to-end drug discovery process and allow for more rapid data turnaround and analysis. The novel metabolomics platform, released in 2018, is an extendable platform that can adapt to many types of data workflows and features an array of applications that can process, analyze, integrate, and visualize biological data across metabolomics, genomics, transcriptomics, and proteomics, among others.
Over the past three years, Elucidata has partnered and rolled-out with 15 biotech and pharmaceutical companies to streamline their drug discovery process.